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The emergence of life-threatening multidrug-resistant (MDR) 
bacteria has been widely documented as a global threat to society, 
because effective antibiotics to treat bacterial infections are rapidly 
diminishing.[1] A global review of antibiotic consumption revealed 
that antibiotic utilisation increased by 36% over a 10-year period 
(2000 - 2010), with the most notable escalation reflected in the 
carbapenem and polymyxin classes.[2] This trend correlates with the 
mounting rates of MDR and extensively drug-resistant (XDR) Gram-
negative pathogens, which include the carbapenemase-producing 
Enterobacteriaceae (CPE), which often require the use of older, more 
toxic drugs such as colistin as last-resort salvage therapy for critically 
ill patients in hospital settings.[3]
Colistin, also known as polymyxin E, is a nephrotoxic and neuro-
toxic, concentration-dependent bactericidal antibiotic. It became 
accessible for use in the late 1950s, but its use diminished over time 
as newer, less toxic agents such as the aminoglycosides became 
available.[4-5] Unfortunately, the current dosing guidelines for colistin, 
with regard to both administration and dose, are outdated, inaccurate 
and confusing, as the package insert information has not been 
revised since its initial launch.[6] This compromises the management 
of patients with serious Gram-negative infections and potentially 
increases resistance.[7] Recommendations also differ between the 
European and American literature, depending on whether the 
metric system has been adopted or not. Either international units or 
milligrams of the sodium salt colistimethate (the inactive prodrug) 
may be used, and to confuse matters further, colistin base activity 
(CBA) in milligrams may also be used to define the dose.[4,6] 
Many believe that the appropriate use of colistin is not known, as 
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Background. Colistin is an old antibiotic that has been reintroduced as salvage therapy in hospitalised patients because it is frequently the 
only agent active against Gram-negative bacteria. Various guidelines for colistin administration have led to confusion in establishing the 
appropriate dose, which has potential for adverse consequences including treatment failure or toxicity. The emergence and spread of colistin 
resistance has been documented in South Africa (SA), but no local information exists on how and why colistin is used in hospitals, and 
similarly, compliance with current dosing guidelines is unknown.
Objectives. To evaluate the current utilisation of colistin in SA hospitals, in order to identify stewardship opportunities that could enhance 
the appropriate use of this antibiotic.
Methods.  Electronic patient records of adult patients on intravenous (IV) colistin therapy for >72 hours in four private hospitals were 
retrospectively audited over a 10-month period (1 September 2015 - 30 June 2016). The following data were recorded: patient demographics, 
culture and susceptibility profiles, diagnosis, and indication for use. Compliance with six colistin process measures was audited: obtaining 
a culture prior to initiation, administration of a loading dose, administration of the correct loading dose, adjustments to maintenance dose 
according to renal function, whether colistin was administered in combination with another antibiotic, and whether de-escalation following 
culture and sensitivity results occurred. Outcome measures included effects on renal function, overall hospital mortality, intensive care unit 
length of stay (LoS), and hospital LoS.
Results. Records of 199 patients on IV colistin were reviewed. There was 99.0% compliance with obtaining a culture prior to antibiotic 
therapy, 93.5% compliance with prescription of a loading dose, and 98.5% compliance regarding prescription of colistin in combination 
with another agent. However, overall composite compliance with the six colistin stewardship process measures was 82.0%. Non-compliance 
related to inappropriate loading and maintenance doses, lack of adjustment according to renal function and lack of de-escalation following 
culture sensitivity was evident. Significantly shorter durations of treatment were noted in patients who received higher loading doses 
(p=0.040) and in those who received maintenance doses of 4.5 MU twice daily v. 3 MU three times daily (p=0.0027). In addition, compared 
with patients who survived, more patients who died received the 3 MU three times daily maintenance dose (p=0.0037; phi coefficient 0.26).
Conclusions.  The study identified multiple stewardship opportunities to optimise colistin therapy in hospitalised patients. Urgent 
implementation of a stewardship bundle to improve colistin utilisation is warranted.
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knowledge of its pharmacokinetics (PK) and pharmacodynamics 
(PD) are incomplete.[8] However, a recent large multicentre PK study 
involving 215 patients described a novel algorithmic approach for 
intravenous (IV) colistin dosing, establishing for the first time dosing 
recommendations based on accurate PK data.[9]
Colistin in South Africa (SA) is only authorised in exceptional 
circumstances following application to and approval from the 
Medicines Control Council, as stipulated in section 21 of the 
Medicines and Related Substances Control Act. This process is often 
associated with delays in drug procurement.[10] Over- or incorrect use 
of antibiotics can lead to the development of resistance[11] and, while 
the emergence and spread of colistin resistance, including hetero-
resistance among CPE (OXA-48 producing Klebsiella pneumoniae) 
and plasmid-mediated resistance, has recently been documented in 
SA,[12-14] the degree of compliance with current dosing guidelines 
is unknown and no local information on why and how colistin is 
prescribed is available. Colistin hetero-resistance is defined as ‘the 
emergence of resistance to colistin by a subpopulation from an 
otherwise susceptible (MIC [minimum inhibitory concentration] 
of ≤2 mg/liter) population’ that may be related to exposure to 
suboptimal polymyxin concentrations.[14]
Objectives
The main purpose of this study was to evaluate the current utilisation 
of colistin in four private sector SA hospitals. We also hoped to 
identify opportunities to improve the appropriate use of colistin in 
the future, in an attempt not only to improve outcomes, but to negate 
or minimise the risk of development of resistance in vivo.
Methods
This multicentre retrospective record review of patients receiving IV 
colistin treatment was conducted in four private sector SA hospitals, 
comprising two each in Johannesburg and Pretoria. The necessary 
approvals for this study were obtained from the individual participating 
hospitals, and ethical clearance (ref. no. M150404) was granted by the 
University of the Witwatersrand Human Research Ethics Committee. 
Hospital names were kept anonymous for ethical reasons.
Data were collected and captured in the electronic Bluebird system 
(http://www.intelms.com/) for a 10-month period (1 September 
2015 - 30 June 2016). This system integrates laboratory data from 
the main private laboratories with dispensing data and the patient’s 
admission master file. This allowed for the identification of patients 
in each hospital to whom colistin had been dispensed, and for the 
monitoring of laboratory culture results, drug prescription data, 
hospital ward movements and overall patient outcomes. The study 
included adult patients aged >18 years who were prescribed IV 
colistin for at least 72 hours. Paediatric and neonatal patients and 
those who received colistin treatment via an alternative route of 
administration were excluded. Following review of patient records 
from the Bluebird system, findings were entered onto a spreadsheet 
using Microsoft Excel version 14 (Microsoft, USA) for statistical 
analysis and qualitative interpretation.
The following patient information was collected: age, gender, 
weight (kg), hospital ward location, admission diagnosis, serum 
creatinine level and estimated glomerular filtration rate (eGFR). The 
indications for colistin therapy were recorded as follows: empirical 
therapy (if no evidence of an MDR or XDR Gram-negative organism 
was found prior to or during the course of treatment), directed 
therapy (infection with an MDR or XDR organism of known 
sensitivity) or salvage therapy (failure of an alternative treatment 
where colistin was used as escalation therapy).
Process and outcome measures
Audit of colistin process measures included the following: obtaining 
a culture prior to colistin initiation, prescription of a loading dose, 
prescription of correct loading and maintenance doses, and adjustments 
of maintenance doses according to renal function as stipulated by two 
SA guidelines,[10,15] administration of colistin in combination with 
another antibiotic, duration of therapy (calculated as number of 
treatment days), and de-escalation following culture and sensitivity 
results. First or repeat courses were also documented, and the type of 
culture specimens, the organisms cultured and the sensitivity profiles 
were matched to the prescription data. Outcome measures included 
were effect on renal function, overall hospital mortality, intensive care 
unit (ICU) length of stay (LoS) and hospital LoS.
Statistical analysis
The relationship between the duration of therapy and other study 
variables was assessed by the t-test, or one-way analysis of variance 
(ANOVA) for more than two categories. Where the data did not 
meet the assumptions of these tests, a non-parametric alternative, the 
Wilcoxon rank-sum test (or the Kruskal-Wallis test for more than two 
categories), was used. The χ2 test was used to assess the relationships 
between patient outcomes and other study variables. Fisher’s exact 
test was used for 2 × 2 tables or where the requirements for the χ2 test 
could not be met. Data analysis was carried out using SAS version 9.4 
for Windows (SAS Institute, USA). The 5% significance level was used.
Results
A total of 212 patients received IV colistin during the study period. 
Of these 13 did so for <72 hours and were therefore excluded. 
Table  1 describes the demographics and characteristics of the patients 
included in the study. The mean age of the patients was 50.9 years 
(standard deviation (SD) 16.9), range 19 - 93). The most common 
admission diagnosis was haematological malignancy (37.2%, n=74) 
followed by trauma (12.1%, n=24) and then bloodstream infection 
(7.5%, n=15). Laboratory culture identification was undertaken from 
197 patients. Blood cultures were the most frequent (54.3%, n=107), 
Table 1. Demographics and characteristics of the patients studied 
(N=199)
Patients, n (%)
Number of patients per hospital
Hospital 1 56 (28.1)
Hospital 2 22 (11.1)
Hospital 3 17 (8.5)
Hospital 4 104 (52.3)
Distribution of patients according to hospital location
General wards 40 (20.1) 
ICUs 159 (79.9) 
Gender
Male 113 (56.8) 
Female 86 (43.2) 
Course of colistin therapy
First course 163 (81.9) 
Repeat course 36 (18.1) 
Indication for colistin therapy
Empirical therapy 63 (31.1) 
Directed therapy 121 (60.8) 
Salvage therapy 15 (7.5) 
ICUs = intensive care units.
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followed by urine (14.7%, n=29), sputum (8.6%, n=17) and tracheal 
aspirates (8.1%, n=16). The most prevalent organisms necessitating 
the use of colistin were K. pneumoniae (39.2%, n=78), Pseudomonas 
aeruginosa (20.1%, n=40) and Acinetobacter baumannii (9.0%, n=18). 
Of these, 77.9% (n=106) were resistant to the carbapenems. The most 
commonly co-administered antibiotics were meropenem (60.7%, 
n=119) and tigecycline (28.6%, n=56). In 63.8% (n=125), 32.1% 
(n=63) and 4.1% (n=8) of patients, one, two and three Gram-negative 
antimicrobial agents, respectively, were prescribed in addition 
to colistin. The median duration of colistin therapy was 9 days 
(interquartile range (IQR) 6 - 16, range 3 - 63). Most patients (57.8%, 
n=115) received a course of therapy of ≤10 days, 13.6% (n=27) a 
course of 11 - 14 days and 28.6% (n=57) a course of ≥15 days.
Process measures
As demonstrated in Table 2, there was considerable variability in both 
the prescribed loading and maintenance doses, as well as in frequency 
of administration. Non-compliance with SA dosing adjustment 
recommendations according to renal function is depicted in Table 3, 
and the audit of compliance with all the colistin process measures is 
summarised in Table 4.
Outcome measures
Durations of treatment were found to be significantly shorter in 
patients who received higher loading doses (p=0.040) (Fig. 1). Those 
who received maintenance doses of 4.5 MU IV 12-hourly v. 3 MU 
IV 8-hourly also had shorter durations of therapy, 8 days v. 12 days, 
respectively (p=0.0027). The duration of therapy for patients with 
P. aeruginosa infection (median 12 days, IQR 8 - 23) was significantly 
longer than for those without (median 9 days, IQR 6 - 15) (p=0.044). 
No significant differences were found in the median duration of 
therapy for patients in the ICU v. the general wards (p=0.41) or 
between those with positive blood culture samples v. other specimen 
types (p=0.39). In addition, no difference was noted regarding 
treatment duration and overall patient outcome (p=0.20).
Table 2. Prescribed LDs and MDs and frequency of administration of colistin in the study patients (N=199)
LD
Patients (N=186),
n (%) MD
Patients (N=199),
n (%)
Frequency of 
administration 
Patients (N=100),
n (%)
4 MU 3 (1.6) 1 MU 3 (1.5) 6-hourly 1 (0.5) 
6 MU 10 (5.4) 1.5 MU 11 (5.5) 8-hourly 76 (38.2) 
8 MU 5 (2.7) 2 MU 17 (8.5) 12-hourly 122 (61.3) 
9 MU 45 (24.2) 2.5 MU 2 (1.0) 
11 MU 1 (0.5) 3 MU 65 (32.7) 
12 MU 122 (65.6) 4.5 MU 101 (50.8) 
LD = loading dose; MD = maintenance dose.
Table 3. Compliance with recommended adjustments of colistin dosage according to renal function
South African Society of Clinical Pharmacy guideline[15]
Normal renal function Loading dose 12 MU, then 3 MU 8-hourly  
or 4.5 MU 12-hourly
CrCl 40 - 60 mL/min 2 MU 12-hourly
CrCl 10 - 40 mL/min 2 MU 24-hourly
CrCl <10 mL/min 1.5 MU 36-hourly
Compliance with recommended dosing guidelines for study patients (N=199), n (%)
Unknown* 58 (29.2)
Compliant 68 (34.2)
Non-compliant 73 (36.7)
Visser Kift et al. guideline[10]
Critically ill or severe sepsis Loading dose 9 - 12 MU
eGFR >60 mL/min 4.5 MU 12-hourly
eGFR 30 - 60 mL/min 3 MU 12-hourly
eGFR 10 - 30 mL/min 2 MU 12-hourly
eGFR <10 mL/min 1 MU 12-hourly
Compliance with recommended dosing guidelines for study patients (N=199), n (%)
Unknown* 3 (1.5)
Compliant 80 (40.2)
Non-compliant 116 (58.3)
CrCl = creatinine clearance; eGFR = estimated glomerular filtration rate.
*Contributions to unknown compliance are a result of data not documented on records for variables including weight and eGFR.
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Fig. 1. Associations between colistin loading dose and median duration of 
treatment. The error bars denote the interquartile range.
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The effects on renal function in patients who received IV colistin 
therapy were insignificant. There was no change in median creatinine 
level after receiving colistin (73 µmol/L, IQR 53 - 110, range 21 - 601 
before; 73 µmol/L, IQR 51 - 128, range 20 - 645 after). Similarly, the 
mean eGFR was 79 mL/min (SD 37, range 8 - 150) before treatment 
and 79 mL/min (SD 38, range 7 - 150) after treatment. Prior to the 
commencement of colistin, 5.6% of patients (n=11) were considered 
to have kidney failure, 7.1% (n=14) to have severe kidney injury, 
and 66.8% (n=131) to have normal kidney function according to the 
Kidney Disease Improving Global Outcomes (KDIGO) classification.
The median ICU LoS was 31 days (IQR 15 - 52, range 0 - 152) 
and the median hospital LoS was 46 days (IQR 25 - 83, range 3 - 
227). The majority of the patients (70.4%, n=140) were discharged, 
indicating a 29.6% in-hospital mortality rate (n=59). This study 
found no significant association between patient outcomes and 
a particular organism, the presence or absence of a bloodstream 
infection, duration of therapy or loading dose. However, a significant 
association was found between outcome and the maintenance dose 
prescribed (p=0.0037; phi coefficient 0.26). Patients who died had 
received lower prescribed maintenance doses per interval than those 
who survived (Fig. 2).
Discussion
To our knowledge this is the first study that has evaluated the current 
utilisation of colistin across multiple SA hospitals and involving a large 
sample of patients. As a result, numerous opportunities for improved 
stewardship were identified. Recent recommendations in response 
to the emergence and spread of plasmid-mediated colistin resistance 
include preserving colistin use for definitive treatment based on 
susceptibility testing, use of PK/PD indicators to ensure appropriate 
dosing, and use of empirical therapy in selected cases only.[16]
Contrary to these recommendations, our study suggests that 
both loading and maintenance dosing of colistin is variable and 
inconsistent, with adherence to available local dosing guidelines at 
best 48.2%. This reveals the extent of uncertainty associated with 
colistin utilisation in SA hospitals and the very urgent need for 
education so that our last-resort Gram-negative antibiotic can be 
preserved for as long as possible. The administration of a colistin 
loading dose is widely considered to be best practice, as it facilitates 
the rapid achievement of optimal bactericidal concentrations.[17,18] 
Although compliance with the recommendation for a loading dose 
was high (93.5%), the actual loading doses ranged from 4 MU to 12 
MU. This demonstrates a lack of understanding regarding the need 
for appropriate loading doses, which should be in the region of 9 - 12 
MU regardless of renal function.[9,19] The findings of our study further 
emphasise the importance of ensuring optimal dosing as, although 
Acute Physiology and Chronic Health Evaluation II (APACHE II) 
scores were not available so that patients could be appropriately 
matched, higher loading doses appeared to be associated with shorter 
duration of treatment. Interestingly, there also appeared to be an 
association with the manner in which the maintenance doses were 
administered. Although most patients received 9 MU/day, those who 
received doses of 4.5 MU twice daily also had a shorter duration of 
therapy and more favourable overall outcomes, which may be due to 
the concentration-dependent nature of the drug. This is in keeping 
with the concept that administration of antibiotics according to 
PK principles and rapid achievement of therapeutic concentrations 
would result in improved clinical cure.[17,20-21]
Combination therapy was prescribed to all but three patients in 
our study. This practice, including duplicate and sometimes triplicate 
therapy, is recommended by local guidelines for the treatment of CPE, 
suggesting that combinations may improve efficacy and minimise the 
risk of selection of resistant organisms. Studies that have supported 
combination therapy for CPE have relatively low sample sizes, and 
concerns remain regarding the increased environmental burden of 
multiple antibiotic exposure, which may actually increase colonisation 
rates with resistant organisms and increase the risk of Clostridium 
difficile infection.[22] One recent study could not demonstrate whether 
it was combination therapy alone rather than higher dosing that 
contributed to better patient outcomes, albeit in a small patient study 
population (N=28).[17] Randomised clinical trials are underway to 
help establish whether patient outcomes are actually improved with 
combinations compared with appropriately dosed and administered 
colistin monotherapy.[17,22] Until these results are available, combination 
therapy is currently the recommended best practice.
Of concern is the large proportion of patients in our study (31.1%) 
who received empirical colistin therapy. This could be due to the 
expectation of increased MDR and XDR infections in the large 
population of severely immunocompromised haematology patients 
Table 4. Compliance with colistin stewardship process measures
Process measures
Compliance rate (N=199),
% (n) 
Obtaining an appropriate culture prior to commencement of colistin therapy 99.0 (197)
Prescription of a loading dose 93.5 (186)
Prescription of an appropriate loading dose 90.3 (168)
Prescription of appropriate maintenance dosing, including adjustment according to renal insufficiency 48.2 (68/141)*
40.8 (80/196)†
Prescription of colistin in combination with another Gram-negative antibiotic 98.5 (196)
De-escalation of colistin therapy 69.9 (58/83)
*According to the South African Society of Clinical Pharmacy guideline.[15]
†According to Visser Kift et al.[10]
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Fig. 2. Associations between colistin maintenance doses and patient outcome.
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included in the study, for whom colistin may well be appropriate. For 
69.9% (n=58) of the eligible patients, therapy was de-escalated to a 
narrower-spectrum antibiotic following the availability of sensitivity 
results. Although this is a somewhat low figure, it is in line with 
other studies indicating that de-escalation is not always possible for 
many reasons, including the limited number of effective antibiotics 
available to treat MDR infections, the limited understanding of how 
to de-escalate, and the fact that the practice has still not been widely 
accepted in critically ill patients.[23]
Colistin-related nephrotoxicity remains an important concern 
and has been found to be influenced by elevated plasma drug 
concentrations (>2.5 mg/L) and longer duration of therapy.[24] Similar 
insignificant effects as in our analysis of renal function have been 
demonstrated.[17] Another study found that up to 43% of patients 
were at risk of or had acute kidney injury or renal failure according to 
the Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) 
criteria after IV colistin therapy; however, this toxicity was reversed 
following discontinuation of treatment.[25] Recent results from the 
multicentre PK colistin study demonstrated that there was huge 
interpatient variability in the clearance of colistin (even at similar 
creatinine clearances), which is probably due to differences between 
individuals in conversion rates of the inactive prodrug to its active 
form.[9] This adds to the complexity of providing optimal dosing, 
given the very narrow therapeutic window of the drug.
Study limitations
Limitations of this study include its retrospective nature and the 
need to collect data from electronic prescription records, which may 
not always record parameters such as renal replacement therapy. 
Furthermore, the high number of patients who did not have their 
weight recorded made it difficult to calculate creatinine clearances 
using the Cockcroft-Gault equation. Compliance with the South 
African Society of Clinical Pharmacy dosing guidelines based on 
creatinine clearance may therefore be skewed. Although not an 
objective of the study, illness severity scores such as the APACHE II 
score were not recorded and patient risk in relation to mortality or 
outcome could therefore not be corrected. The median duration of 
colistin therapy in this study was 9 days. In these scenarios, treatment 
courses are typically determined at the discretion of the prescribing 
clinician, and this commonly depends on the clinical response to 
therapy and/or evidence of microbiological cure. As such, duration 
of therapy could not be used as a process indicator owing to the 
limited guidance available on what an appropriate duration should 
be. In addition, the dosing duration may have been a function of 
prescriber education rather than an indication that higher loading 
doses were associated with a more rapid clinical response. Finally, 
data on side-effects of colistin other than nephrotoxicity were not 
actively investigated.
Conclusions
This study showed that multiple stewardship opportunities for 
improvement exist, including administration of appropriate colistin 
loading and maintenance doses, optimising maintenance doses 
according to renal function, prioritising culture-driven prescribing 
where possible, and monitoring of combination therapy, de-escalation 
practices and duration of treatment to preserve colistin efficacy for 
the foreseeable future. The introduction of colistin therapeutic drug 
monitoring would be extremely useful to individualise dosing, given 
the variability of PK and PD parameters in critically ill patients. As 
an immediate solution, however, the design of a colistin antimicrobial 
stewardship bundle to increase composite compliance could have a 
significant impact and is strongly recommended.
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